UBS Group AG lessened its position in USANA Health Sciences, Inc. (NYSE:USNA) by 13.0% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 122,069 shares of the company’s stock after selling 18,201 shares during the period. UBS Group AG owned 0.50% of USANA Health Sciences worth $10,486,000 at the end of the most recent reporting period.
Other institutional investors have also recently made changes to their positions in the company. Swiss National Bank boosted its stake in shares of USANA Health Sciences by 10.1% during the 4th quarter. Swiss National Bank now owns 19,600 shares of the company’s stock valued at $1,451,000 after purchasing an additional 1,800 shares in the last quarter. UBS Asset Management Americas Inc. bought a new stake in shares of USANA Health Sciences during the 4th quarter valued at about $478,000. Fort L.P. boosted its stake in shares of USANA Health Sciences by 7,199.2% during the 4th quarter. Fort L.P. now owns 52,189 shares of the company’s stock valued at $3,865,000 after purchasing an additional 51,474 shares in the last quarter. Teacher Retirement System of Texas bought a new stake in shares of USANA Health Sciences during the 4th quarter valued at about $282,000. Finally, Teachers Advisors LLC boosted its stake in shares of USANA Health Sciences by 1.2% during the 4th quarter. Teachers Advisors LLC now owns 211,824 shares of the company’s stock valued at $15,686,000 after purchasing an additional 2,506 shares in the last quarter. 48.39% of the stock is currently owned by institutional investors and hedge funds.
In other USANA Health Sciences news, Director Myron W. Wentz purchased 6,697 shares of the stock in a transaction that occurred on Friday, December 7th. The stock was bought at an average cost of $70.46 per share, with a total value of $471,870.62. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, major shareholder Global Ltd Gull sold 40,000 shares of USANA Health Sciences stock in a transaction dated Tuesday, April 3rd. The shares were sold at an average price of $86.23, for a total transaction of $3,449,200.00. Following the transaction, the insider now directly owns 11,214,053 shares of the company’s stock, valued at $966,987,790.19. The disclosure for this sale can be found here. Over the last three months, insiders have purchased 19,117 shares of company stock valued at $1,349,965 and have sold 1,054,810 shares valued at $117,978,219. Company insiders own 48.00% of the company’s stock.
A number of equities research analysts have recently weighed in on USNA shares. ValuEngine raised shares of USANA Health Sciences from a “hold” rating to a “buy” rating in a research note on Wednesday, May 2nd. TheStreet raised shares of USANA Health Sciences from a “c+” rating to an “a-” rating in a research note on Tuesday, April 24th. Finally, Pivotal Research lowered shares of USANA Health Sciences from a “buy” rating to a “hold” rating and set a $95.00 target price on the stock. in a research note on Monday, April 23rd. They noted that the move was a valuation call. One research analyst has rated the stock with a sell rating, two have given a hold rating and one has issued a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $95.00.
Shares of USNA opened at $117.10 on Wednesday. The stock has a market cap of $2.79 billion, a PE ratio of 28.84 and a beta of 0.73. USANA Health Sciences, Inc. has a 1-year low of $52.80 and a 1-year high of $121.15.
USANA Health Sciences (NYSE:USNA) last announced its earnings results on Tuesday, April 24th. The company reported $1.19 earnings per share for the quarter, beating analysts’ consensus estimates of $1.05 by $0.14. The firm had revenue of $292.00 million for the quarter, compared to analyst estimates of $268.93 million. USANA Health Sciences had a net margin of 6.47% and a return on equity of 27.92%. The company’s revenue for the quarter was up 14.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.91 EPS. sell-side analysts forecast that USANA Health Sciences, Inc. will post 4.4 earnings per share for the current fiscal year.
USANA Health Sciences Profile
USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional and personal care products primarily to reduce the risk of chronic degenerative disease. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include low-glycemic meal replacement shakes, snack bars, and other related products, which provide macro-nutrition.
Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.